Wall Street's Wild New Stock Picks Unveiled!

Wall Street's Fresh Holy Trinity of "WTF Is This Stock Smoking?" – November 11, 2026 Edition

Back at it, you beautiful degenerates. Markets are the same glorious shitshow—AI hype juicing the Nasdaq while the Dow sits on its ass like a retiree in Boca, and crude oil bounces around like a drunk on a pogo stick. I scoured the freshest short-interest scans and signals (including live borrow vibes and volatility overlays from recent settlement data) for three brand-new names where the bears are piled higher than a Wall Street bonus pool on a bad year, and the bulls are yelling “squeeze me harder.” No repeats of the usual suspects. Just pure, unfiltered fresh meat with serious short pressure and “prove me wrong, bitch” vibes. Here’s today’s unholy trinity.[1]

1. UAA (Under Armour): The Athletic Apparel Underdog That’s Either Reclaiming Its Performance Roots or Getting Crushed by Nike, Lululemon, and Its Own SKU Chaos

The Bull Case (Reset Discipline + Margin Magic + Squeeze Juice):
Bulls are pumped on Under Armour’s aggressive reset—massive SKU cuts, youth licensing shift, AI-driven operations, and a laser focus on core performance apparel (HEATGEAR/COLDGEAR) with pricing power and higher ASPs. Recent results showed sales declines but a sharply reduced net loss, with management claiming the worst of the disruption is behind them and guiding for operating income targets that could double. Any execution wins, inventory cleanup success, or sector rotation into value retail could trigger a short squeeze (short signals showing ~36% of float shorted in recent scans). “We’ve got the brand DNA, the cost discipline, and the asymmetric upside—watch the shorts get UAA’d when margins expand” is the battle cry.[2]

The Bear Case (Structural Shrinkage, Footwear Drag, and Classic Retail Binary Hell):
Reality check: Brutal questions on whether the “reset” can offset ongoing revenue declines (mid-single-digit drops guided), persistent footwear weakness, promotional dependency, and competition from tighter, more profitable rivals. Guidance cuts on gross margins amid higher freight and inventory actions highlight the risks, with one-time tariff refunds and reserve reversals propping things up temporarily. High short pressure reflects the market’s “yeah, right” on flawless execution in a hyper-competitive space where demand keeps eroding. One more traffic miss or deeper discounting and it’s pain. Under Armour? More like “Under Water—shorts are harvesting the downside.”

My First-Principles Breakdown:
Strip it down: Apparel/retail plays win on defensible brand moats, disciplined inventory and assortment management, resilient pricing power across cycles, and actual operational execution—not just “athleisure hype” buzz. UAA has real heritage in performance gear and is finally attacking over-assortment, but “success” requires proving the reset sticks without endless promotions or losing core customers. Shorts correctly price in the competitive and demand risks; bulls correctly price in the margin upside if SKU discipline delivers. High-vol consumer bet—entertaining as hell, size accordingly or cry into your empty sneaker closet later.

2. IBRX (ImmunityBio): The Cancer Immunotherapy Biotech That’s Either Delivering ANKTIVA Breakthroughs or Getting Burned by Clinical Risks and Cash Inferno

The Bull Case (Oncology Platform + Partnership Momentum + Squeeze Fuel):
Bulls are fired up on ImmunityBio’s ANKTIVA (for bladder cancer and beyond) with recent marketing authorizations (e.g., UAE), growing sales potential, and a broader NK cell therapy platform. Any positive clinical readouts, partnership expansions, or sector rotation into biotechs could spark a short squeeze (short signals flagging ~30-31% of float shorted with elevated days-to-cover in recent data). “We’ve got the immune activation tech, the regulatory wins, and the hype—watch the shorts get IBRX’d when adoption accelerates” is the mantra.[3]

The Bear Case (Single-Asset Binary, Dilution Dragon, and Classic Biotech Cash Burn Hell):
Reality bites: Brutal risks from ongoing cash burn, questions on sustainable revenue ramps amid competition in oncology, high short pressure reflecting skepticism on flawless execution and long commercialization timelines. Recent earnings misses and sales fluctuations underscore the volatility. One funding crunch, trial setback, or hype fade and it’s pain. ImmunityBio? More like “Immunity No—shorts are harvesting the downside.”

My First-Principles Breakdown:
Fundamentally, biotech plays win on validated mechanisms, diversified pipelines or strong single-asset data, resilient capital access across cycles, and actual clinical/regulatory discipline—not just “cancer cure” buzz. IBRX has real oncology exposure and early wins, but “breakout” requires surviving burn rates, proving durable efficacy/sales at scale, and outpacing rivals without excessive dilution. Shorts correctly flag the execution and funding risks; bulls correctly flag the asymmetric upside if platforms deliver. High-vol biotech bet—entertaining as hell, size accordingly or cry into your empty lab notebook later.

3. PROK (ProKidney): The Kidney Disease Cell Therapy Upstart That’s Either Cracking CKD Treatment or Getting Decohered by Single-Asset Risk, Dilution, and a Dwindling Runway

The Bull Case (Pivotal Data Potential + Massive Unmet Need + Squeeze Juice):
Bulls are creaming over ProKidney’s rilparencel (autologous cell therapy) for diabetic kidney disease, with Phase 3 PROACT-1 readout eyed for 2027 and a huge addressable market. Any positive data, analyst upgrades, or deep-tech/biotech rotation could trigger a short squeeze (short signals highlighting elevated pressure and very high days-to-cover in recent scans, with notable % of float). “We’ve got the cell therapy edge, the CKD tailwinds, and the asymmetric upside—watch the shorts get PROK’d when trials hit” is the hype.[4]

The Bear Case (Single-Asset Doom, Cash Burn Inferno, and Classic Biotech Binary Hell):
Reality check: Brutal questions on Phase 2 data strength, single-asset concentration, ongoing high burn with runway questions into mid-2027, and dilution risks from recent shelf filings/ATM programs. High short pressure reflects the market’s “yeah, right” on flawless execution in a long-horizon, high-risk space. One trial miss, funding crunch, or data delay and it’s pain. ProKidney? More like “Pro the losses—shorts are harvesting the downside.”

My First-Principles Breakdown:
Kidney/biotech plays win on compelling mechanisms with clean data, diversified or de-risked assets, resilient capital structure across cycles, and actual clinical discipline—not just “kidney cure” buzz. PROK has real exposure to a massive unmet need, but “success” requires surviving burn and dilution, proving pivotal data at scale, and outpacing rivals without endless equity raises. Shorts correctly price in the binary and funding risks; bulls correctly price in the asymmetric upside if Phase 3 delivers. High-vol deep-biotech bet—entertaining as hell, size accordingly or cry into your empty dialysis chair later.

Bottom Line (No Crystal Ball, Just Brutal Logic):
These three capture the current divided vibe: apparel reset gamble, oncology platform rodeo, and kidney cell therapy binary. The common thread? Sky-high skepticism via short signals and volatility, but real catalysts that could flip the script. Markets adore punishing uncertainty—and these names are marinated in it. Laugh at the chaos, size positions like your rent depends on it (or don’t), and remember: this is entertainment with numbers. Your move, degenerates.

Sources for the terminally curious (verify this shit yourself): Recent short-interest trackers and signals (e.g., ChartMill most-shorted screens, Tapeboard, Lician, AltIndex) highlighting elevated pressure in UAA, IBRX, and PROK; company updates, earnings commentary, analyst notes, and filings on sector debates. Always do your own digging—these are snapshots of a deranged market. Trade responsibly, or at least don’t cry when it goes tits up.